Breast cancer and melanoma cell line identification by FTIR imaging after formalin-fixation and paraffin-embedding.

Auteurs : Verdonck M, Wald N, Janssis J, Yan P, Meyer C, Legat A, Speiser DE, Desmedt C, Larsimont D, Sotiriou C, Goormaghtigh E
Jaar : 2013
Journal : Analyst
Volume : 138(14)
Pagina's : 4083-91

Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial.

Auteurs : Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber Rd, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M
Jaar : 2013
Journal : J. Clin. Oncol.
Volume : 31(16)
Pagina's : 1954-60

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.

Auteurs : Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart-Gebhart M, Sotiriou C
Jaar : 2013
Journal : PLoS One
Volume : 8(8)
Pagina's : e66848

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.

Auteurs : Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Müller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
Jaar : 2013
Journal : Breast Cancer Res
Volume : 15(5)
Pagina's : R86

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Auteurs : Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A
Jaar : 2013
Journal : Future Oncol
Volume : 9(10)
Pagina's : 1477-87

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial.

Auteurs : Azim HA, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, Toral-Peña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M
Jaar : 2013
Journal : Breast
Volume : 22(6)
Pagina's : 1060-5

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.

Auteurs : Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart-Gebhart M, Sotiriou C
Jaar : 2013
Journal : PLoS One
Volume : 8(1)
Pagina's : e53292

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98.

Auteurs : Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart-Gebhart M, Sotiriou C
Jaar : 2013
Journal : J. Clin. Oncol.
Volume : 31(7)
Pagina's : 860-7

Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.

Auteurs : Bertucci F, Finetti P, Roche H, Le Doussal JM, Marisa L, Martin AL, Lacroix-Triki M, Blanc-Fournier C, Jacquemier J, Peyro-Saint-Paul H, Viens P, Sotiriou C, Birnbaum D, Penault-Llorca F
Jaar : 2013
Journal : Ann Oncol
Volume : 24(3)
Pagina's : 625-32

Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer.

Auteurs : Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S
Jaar : 2013
Journal : Clin Cancer Res
Volume : 19(1)
Pagina's : 28-33

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

Auteurs : Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, van de Vijver M, Viale G, Loi S, Reis-Filho JS
Jaar : 2012
Journal : Ann Oncol
Volume : 23
Pagina's : 2997-3006

Dissecting the heterogeneity of triple-negative breast cancer.

Auteurs : Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M
Jaar : 2012
Journal : J. Clin. Oncol.
Volume : 30(15)
Pagina's : 1879-87

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Auteurs : Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart-Gebhart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y
Jaar : 2012
Journal : Oncogene
Volume : 31(31)
Pagina's : 3569-83

Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.

Auteurs : Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G
Jaar : 2012
Journal : Breast
Volume : 21(1)
Pagina's : 20-6

The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study.

Auteurs : Azim HA, Botteri E, Renne G, Dell orto P, Rotmensz N, Gentilini O, Sangalli C, Pruneri G, Di Nubila B, Locatelli M, Sotiriou C, Piccart-Gebhart M, Goldhirsch A, Viale G, Peccatori F
Jaar : 2012
Journal : Acta oncol (Stockholm)
Volume : 51(5)
Pagina's : 653-61

Minimal residual disease and circulating tumor cells in breast cancer: open questions for research.

Auteurs : Ignatiadis M, Sotiriou C, Pantel K
Jaar : 2012
Journal : Recent Results Cancer Res.
Volume : 195
Pagina's : 3-9

Understanding the biology of triple-negative breast cancer.

Auteurs : Criscitiello C, Azim HA, Schouten PC, Linn SC, Sotiriou C
Jaar : 2012
Journal : Ann Oncol
Volume : 23 Suppl 6
Pagina's : vi13-vi18

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.

Auteurs : Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart-Gebhart M
Jaar : 2012
Journal : Lancet Oncol
Volume : 13(6)
Pagina's : e240-8

Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling.

Auteurs : Azim HA, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart-Gebhart M, Sotiriou C, Loi S
Jaar : 2012
Journal : Clin Cancer Res
Volume : 18(5)
Pagina's : 1341-51

Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment.

Auteurs : Desmedt C, Majjaj S, Kheddoumi N, Singhal SK, Haibe-Kains B, El Ouriaghli F, Chaboteaux C, Michiels S, Lallemand F, Journe F, Duvillier H, Loi S, Quackenbush J, Dekoninck S, Blanpain C, Lagneaux L, Houhou N, Delorenzi M, Larsimont D, Piccart-Gebhart M, Sotiriou C
Jaar : 2012
Journal : Clin Cancer Res
Volume : 18(4)
Pagina's : 1004-14